Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Sarepta: Should Investors Run For The Exit?
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
pharmaphorum2d
Sarepta slumps on Elevidys patient death
The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...
BioPharma Dive3d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Analysts remain optimistic about Elevidys after Sarepta reports patient death
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only ...
GEN - Genetic Engineering and Biotechnology News2d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
BioSpace1d
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
Fierce Pharma3d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne ...
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.